MedTrace Logo

Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease

NCT03145623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-02-15

No results posted yet for this study

Summary

Retrospective Efficacy and Safety Study With Elbasvir (EBR) 50 mg/Grazoprevir (GZR) 100 mg in Hepatitis C Virus (HCV)-infected Patients With Chronic Kidney Disease (CKD) Stage 4-5 During the French Temporary Authorization for Use (ATU) Program: Data From Real-life

Conditions

  • Hepatitis C
  • Chronic Kidney Diseases

Interventions

DRUG

Elbasvir and Grazoprevir

Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program

Sponsors & Collaborators

  • MSD France

    collaborator INDUSTRY

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Laurent ALRIC, MD · University Hospital, Toulouse

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03145623 on ClinicalTrials.gov